Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007

Ann Rheum Dis. 2007 Nov;66 Suppl 3(Suppl 3):iii2-22. doi: 10.1136/ard.2007.081430.

Authors

D E Furst¹, F C Breedveld, J R Kalden, J S Smolen, G R Burmester, J Sieper, P Emery, E C Keystone, M H Schiff, P Mease, P L C M van Riel, R Fleischmann, M H Weisman, M E Weinblatt

Affiliation

¹ David Geffen School of Medicine, UCLA - RM 32-59, 1000 Veteran Avenue, Los Angeles, CA 90025, USA. defurst@mednet.ucla.edu

No abstract available

Publication types

Consensus Development Conference
Review

MeSH terms

Abatacept
Antibodies, Monoclonal / adverse effects
Antibodies, Monoclonal / therapeutic use
Antibodies, Monoclonal, Murine-Derived
Antirheumatic Agents / adverse effects
Antirheumatic Agents / therapeutic use*
Arthritis / drug therapy*
Arthritis, Juvenile / drug therapy
Arthritis, Psoriatic / drug therapy
Arthritis, Rheumatoid / drug therapy
Humans
Immunoconjugates / adverse effects
Immunoconjugates / therapeutic use
Interleukin-1 / antagonists & inhibitors
Neoplasms / chemically induced
Rituximab
Spondylitis, Ankylosing / drug therapy
Tuberculosis / chemically induced
Tumor Necrosis Factor-alpha / antagonists & inhibitors

Substances

Antibodies, Monoclonal
Antibodies, Monoclonal, Murine-Derived
Antirheumatic Agents
Immunoconjugates
Interleukin-1
Tumor Necrosis Factor-alpha
Rituximab
Abatacept